| Part 1:Evaluation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor to Treat Patients with Advanced Non-small Cell Lung CancerObjective:To evaluate the efficacy and safety of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat patients with advanced non-small cell lung cancer (NSCLC).Methods:The clinical characteristics, responses rate, disease control rate and overall survival were retrospectively analyzed in 160 chemonaive patients with advanced NSCLC. All of the patients received oral gefitinib (250mg/d) or erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurrence.Results:The overall responserate was 33.8% and the disease control rate was 74.4%. The median progression-free survival and the median survival time were 9.8 months and 14.5 months, respectively. One-year survival rate was 55%. Responses correlated significantly with histology, PS score, smoking history, skin rash, EGFR mutations and serum CEA. Histology was the independent predictor of progression-free survival and PS score were the independent predictors of survival. Common toxicities were skin rash and mild diarrhea.Conclusion:EGFR-TKI is safe and effective to treat patients with advanced non-small cell lung cancer.Part 2:Preliminary Study of DNA methylation in Lung Cancer MetastasisObjective:To study the relationship between DNA methylation and lung cancer metastasis.Methods:Using NimbleGen methylation assay, to analyse difference between the two lung cancer cell strains with different metastasis potentials in gene methylation.Results:There were differences between 95C and 95D cell strains in methylation of 826 genes involved in cell differentiation, cell proliferation, cell growth, angiogenesis, vascular morphology, angiogenesis, cell adhesion and cell growth.Conclusion:The DNA Methylation might be involved in lung cancer metastasis. |
PDF Full Text Request